Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring

Title

Novo Nordisk Partners with Telehealth Leaders to Expand Affordable Access to Wegovy

Novo Nordisk has partnered with major telehealth companies—including Hims & Hers Health, LifeMD, and Ro—to expand the distribution of its FDA-approved weight-loss drug Wegovy (semaglutide) to self-pay patients in the United States1 5.
These partnerships allow patients to access Wegovy via the companies' telehealth platforms, with prescriptions filled and shipped through Novo Nordisk's own NovoCare Pharmacy, launched in March 20251 2 5.
All dose strengths of Wegovy are available, with the drug now offered at a significantly reduced self-pay price of $499 per month—compared to the previous list price of around $1,350—for both home delivery and retail pharmacy pick-up1 3 4.
Telehealth providers Hims & Hers, LifeMD, and Ro can now offer their patients convenient access to authentic Wegovy, bypassing previous controversies over compounded semaglutide and focusing on distributing the brand-name product directly4.
The collaboration is intended to make weight-loss treatment more accessible and convenient, especially for the approximately 100 million Americans living with obesity1 5.
Wegovy is indicated for chronic weight management in adults and adolescents with obesity, and adults with overweight who have at least one weight-related comorbidity. It is also approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease5.